# Carcell Biopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/carcell-biopharma

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Total disclosed funding: $16M
- Latest round: Seed (Nov 2, 2021)
- Investors on record: 3

## About

Established in 2021 and based in Shanghai, China, Carcell Biopharma is a biomedical company that focuses on research and development of cell and gene therapy. The company was co-founded by Mr. Xiangqian Lin chairman and founder of EVX Ventures and Dr. Jiahai Shi, City University of Hong Kong. The company is headquartered in Shanghai and has a research and development base in Singapore. In November 2023, the firm raised pre-series A funding led by new investor Jinkong Qiyuan Capital. Other new investor Jiayi Investment also participated in the round.

The company's main products include engineered red blood cell platforms for protein delivery and LNP platforms for nucleic acid delivery. Engineered red blood cell platform to deliver proteins for developing immune tolerance mechanisms in autoimmune diseases.



The company will use the pre-series Afunding to advance the red blood cell product to complete IIT clinical trials and advance to IND filing as soon as possible, as well as continue to develop the lipid nanoparticle (LNP) platform with global intellectual property rights.

## Funding rounds

- Seed, Nov 2, 2021, $16M — Legend Star, BioTrack Capital, Hyfinity Investments

## Investors

- Legend Star (https://capitalatlas.ai/funds/legend-star) — Seed
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Seed
- Hyfinity Investments (https://capitalatlas.ai/funds/hyfinity-investments) — Seed